Pediatric Vouchers Could Limit Adult Rare Disease Development, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency expands its critique of voucher incentive that it feels is a strain on agency resources.
You may also be interested in...
Priority Review Vouchers: Does Novartis Have User's Regret?
Stakeholders are sympathetic to FDA's concerns that voucher program requires diversion of precious resources, but some believe it provides substantial drug development incentive, particularly for small companies.
Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.